ARHGDIA

Across TCGA pan-cancer cohorts, ARHGDIA mass-spec protein is linked to patient survival in 6 of 34 cancer types, making it a survival-associated ARHGDIA data layer compared with 27 for mass-spec protein and 8 for mutation status.

The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where higher ARHGDIA mass-spec protein is associated with better disease-free survival. In most high-consensus cancer types, elevated ARHGDIA expression acts as an unfavorable survival marker, although some lineages such as CCRCC and PDAC show a favorable association.

CCRCC, COAD, and PDAC are the cancer types where ARHGDIA mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
CCRCC	DFS	Quartile	III,IV	0.683	0.292	.008	37	view →
COAD	DFS	Median	II,III,IV	0.879	1.000	.019	24	view →
PDAC	DFS	Median	III,IV	0.722	0.365	.022	16	view →
LUAD	OS	Median	III,IV	0.216	0.674	.006	7	view →
HNSC	DFS	Median	II,III,IV	0.904	0.982	.024	2	view →
LSCC	OS	Median	All	0.767	1.000	.015	1	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

ARHGDIA–CCRCC (DFS)

Open the CCRCC breakdown →